The GSK RTS,S vaccine was formally approved by the WHO this week, thereby adding a malaria vaccine to the malaria toolkit for the first time ever. This is a major achievement for the malaria research community and could help protect those living at risk of this devastating parasite. The rollout of RTS,S is expected to help reduce malaria morbidity and mortality. At the same time, efforts to develop even more effective malaria vaccines are underway in our laboratory and others throughout the world. Dr. Murphy was asked to comment on WHO's announcement by numerous news agencies this week including BBC World News, National Geographic, NPR, and local Seattle TV stations and our lab team got to show off some of our facilities and malaria research tools to the press (see Dr. Reynolds below in the insectary). It's a great week for malaria research and exciting to see this first generation RTS,S malaria vaccine reach this giant approval step!
Comments are closed.
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |